Undiscovered and Undervalued Penny Picks

[25 Kilos of Gold]

CTIX Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results. Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results. Link to CTIX 10-K
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
A rally wave continuation, or a third rally wave up to blue-sky territory is likely.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.

Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm

Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis

Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference

Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)